Abstract 1378P
Background
The management of non-small cell lung cancer (NSCLC) has transformed over the past decade through the development of immunotherapy and targeted therapies. Our objective was to evaluate the gains in survival in stage IV NSCLC by sociodemographic groups in the United States.
Methods
Patients diagnosed with and treated for Stage IV NSCLC between 2010 and 2020 in the National Cancer Database were studied in 3 eras (2010 - 2013, 2014 - 2017, and 2018 - 2020). Unadjusted survival was assessed by Kaplan Meier and stratified cox analysis was performed to evaluate differences in survival by race and ethnicity.
Results
Overall, 374,273 patients were identified. The median survival was highest across all 3 eras for Asians (12.9, 17.0, and 22.5 months) and the lowest for American Indians/Alaskan Natives (6.9, 6.9, and 9.0 months) (Table). Survival increased for all racial/ethnicity groups across eras, consistent with the development of novel therapeutics, but with considerable differences in the proportionality of gains. For example, between era 1 and 3, Hispanics experienced an 81% increase in median survival, while American Indians/Alaskan Natives experienced a 30% increase (Table). Multivariable Cox models also demonstrated considerable variability in mortality risk over time, favoring groups other than non-Hispanic white patients with the exception of American Indians/Alaskan Natives.
Table: 1378P
| 2010-2013 | 2014-2017 | 2018-2020 | |||||
| Median survival | Hazard ratio/P Value | Median survival | Hazard ratio/P Value | Median survival | Hazard ratio/P Value | % Difference in median survivalEra 3 &1 | |
| Asian | 12.8 | 0.69 (ConclusionsThere has been a dramatic improvement in survival among stage IV NSCLC over the past decade across all race and ethnicity. The rates of improvement in survival were observed to differ across sociodemographic groups, with the Hispanic patients experiencing the highest benefit. Further studies to understand variability in survival gains by type of therapy or by mutation status are warranted to understand the long-term potential disparities in cancer-related mortality. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyD. Boffa. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest. Resources from the same session1352P - Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapyPresenter: Marco Russano Session: Poster session 06 1353P - Efficacy and safety of docetaxel in combination with nintedanib or ramucirumab following immune checkpoint-Inhibitor treatment in patients with non-small cell lung cancerPresenter: Konstantinos Ferentinos Session: Poster session 06 1354P - Retrospective audit to determine the effect of antibiotic therapy on immune checkpoint inhibitor efficacy in stage IV NSCLCPresenter: Deevyashali Parekh Session: Poster session 06 1356P - Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysisPresenter: Elba Marin Session: Poster session 06 1357P - Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE studyPresenter: Hiroshige Yoshioka Session: Poster session 06 1358P - Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trialPresenter: Trevor Feinstein Session: Poster session 06 1359P - Lack of Abscopal effect and radiotherapy-induced lymphocyte depletion in advanced non-small cell lung cancer (NSCLC) patients treated with atezolizumab and radiotherapyPresenter: Alexander Meisel Session: Poster session 06 1361P - The Stereotactic Radiosurgery-Brain Prognostic Index (SRS-BPI): A novel prognostic index for lung cancer patients with brain metastases eligible for SRSPresenter: Andreas Koulouris Session: Poster session 06 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||||